会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • COLD-ROLLED STEEL SHEET AND PROCESS FOR PRODUCING THE SAME
    • 冷轧钢板及其制造方法
    • US20090300902A1
    • 2009-12-10
    • US12519539
    • 2006-12-20
    • Nobuko MinejiReiko SugiharaTadashi Inoue
    • Nobuko MinejiReiko SugiharaTadashi Inoue
    • H01M6/00C21D8/04C22C38/04
    • C21D9/46C22C38/004C22C38/04Y10T29/49108
    • A cold-rolled steel sheet that is suitable for battery cases and has low anisotropy is composed of, by mass %, C: ≦0.0030%, Si: ≦0.02%, Mn: 0.15 to 0.19%, P: ≦0.020%, S: ≦0.015%, N: ≦0.0040%, Al: 0.020 to 0.070%, Nb: 1.00≦Nb/C (atomic equivalent ratio)≦5.0, B: 1 ppm≦B-(11/14)N≦15 ppm (in the expression, B and N denote the contents of the respective elements), and the balance: being Fe and inevitable impurities, and has a planar anisotropy Δr of the r-value in the range of −0.10≦Δr≦0.10. In a process for producing the steel sheet, the cold rolling is performed at a rolling ratio of 70 to 87%, and then annealing is performed on a continuous annealing line at an annealing temperature of from the recrystallization temperature to 830° C.
    • 适用于电池壳体并且各向异性低的冷轧钢板以质量%计含有C:<= 0.0030%,Si:<= 0.02%,Mn:0.15〜0.19%,P:<0.020 %,S:<= 0.015%,N:<= 0.0040%,Al:0.020〜0.070%,Nb:1.00 <= Nb / C(原子当量比)<= 5.0,B:1ppm <= B- / 14)N <= 15ppm(在表达式中,B和N表示各元素的含量),余量为Fe和不可避免的杂质,并且在r值范围内具有平面各向异性Deltar -0.10 <= Deltar <= 0.10。 在钢板的制造方法中,以轧制率为70〜87%进行冷轧,然后在从再结晶温度至830℃的退火温度下在连续退火生产线上进行退火。
    • 10. 发明申请
    • Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists
    • US20060100460A1
    • 2006-05-11
    • US11270780
    • 2005-11-09
    • Tadashi InoueSatoshi NagayamaKazunari Nakao
    • Tadashi InoueSatoshi NagayamaKazunari Nakao
    • C07D211/26A61K31/445A61K31/18C07C311/19
    • C07C311/08C07C2601/02C07C2602/08C07C2602/10C07D295/096C07D311/16
    • This invention provides a compound of the formula (I): wherein R1 represents a (C1-C6)alkyl group; R2 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C1-C6) alkyl group or a (C1-C6) alkoxy group; R3, R4, R5 and R6 each independently represents a hydrogen atom, a (C1-C6) alkyl, or a halogen atom; R7 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C1-C6) alkyl group optionally substituted with a piperidino group, a (C-1-C6)alkoxy group optionally substituted with a 3-7 membered cycloalkyl ring, a hydroxy(C1-C6)alkoxy group, a (C1-C6)alkoxy-(C1-C6)alkyl group, a (C1-C6)alkoxy-(C1-C6)alkoxy group, a halo (C1-C6)alkyl group, a (C1-C6)alkylthio group, a (C1-C6)alkylsulfinyl group or a (C1-C6)alkylsulfonyl group; R5 represents a (C1-C6)alkyl group, a halo(C1-C6)alkyl group, a (C1-C6)alkoxy group, a hydroxy(C1-C6)alkoxy group, a (C1-C6)alkoxy-(C1-C6)alkyl group or a (C1-C6)alkoxy-(C1-C6)alkoxy group; or R7 and R8, when adjacent to each other, taken together with the carbon atoms to which they are attached form a 5-8 membered carbocyclic or heterocyclic ring, wherein the carbocyclic ring or the heterocyclic ring is unsubstituted or substituted with one or more substituents selected from the group consisting of a hydroxy group, a (C1-C6)alkyl group, a (C1-C6)alkoxy group and a hydroxy(C1-C6)alkyl group; and R9 represents a hydrogen atom or a halogen atom; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor, such as pain or the like in mammalian. The present invention also provides a pharmaceutical composition comprising the compound of formula (I).